Drug interactions
Influenza virus vaccine quadrivalent intranasal + Obinutuzumab
Severity: Major
Influenza virus vaccine quadrivalent intranasal and Obinutuzumab: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Intranasal influenza vaccine contains live attenuated virus, which may replicate excessively in patients with B-cell depletion. The vaccine response may also be poor.
What this interaction means in plain words
Influenza virus vaccine quadrivalent intranasal and Obinutuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Obinutuzumab-induced B-cell depletion impairs immunity, increasing risk from live attenuated virus and reducing vaccine response.
What to do
Use an inactivated injectable influenza vaccine instead of the live intranasal one. Ideally vaccinate at least 2 to 4 weeks before obinutuzumab where feasible.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Influenza virus vaccine quadrivalent intranasal and Obinutuzumab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Obinutuzumab
Frequently asked questions
Can I take Influenza virus vaccine quadrivalent intranasal with Obinutuzumab?
MediHelp rates the interaction as major. Influenza virus vaccine quadrivalent intranasal and Obinutuzumab can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Intranasal influenza vaccine contains live attenuated virus, which may replicate excessively in patients with B-cell depletion. The vaccine response may also be poor.
How serious is the interaction between Influenza virus vaccine quadrivalent intranasal and Obinutuzumab?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Use an inactivated injectable influenza vaccine instead of the live intranasal one. Ideally vaccinate at least 2 to 4 weeks before obinutuzumab where feasible.
What other medicines interact with Obinutuzumab?
MediHelp also lists interactions of Obinutuzumab with, for example, Measles mumps and rubella vaccine, Adenovirus types 4 and 7 live, Axicabtagene ciloleucel. The full list is on the Obinutuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
